Skip to main
AVTX

Avalo Therapeutics (AVTX) Stock Forecast & Price Target

Avalo Therapeutics (AVTX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Avalo Therapeutics has demonstrated significant pre-market momentum, with a notable increase of approximately 22%, driven by growing investor confidence in the company's anti-IL-1B monoclonal antibody, AVTX-009, particularly regarding its potential applications in inflammatory diseases. The anticipation surrounding the forthcoming LOTUS data readout underlines the market's increasing recognition of AVTX-009's efficacy in treating hidradenitis suppurativa (HS), suggesting a favorable environment for potential market expansion. Additionally, the broader therapeutic landscape for HS appears to be evolving, creating opportunities for Avalo Therapeutics as access to more effective and durable therapies grows.

Bears say

Avalo Therapeutics's stock outlook is negatively influenced by concerns regarding safety, as the reported incidence of neutropenia in 4.3% of cases, including instances of Grade 3 decreases in neutrophil counts, may raise regulatory scrutiny and impact the medication's acceptance in the market. Additionally, the presence of target distraction due to lutikizumab's binding to both IL-1β and IL-1α could potentially hinder its effectiveness, complicating its therapeutic profile. Furthermore, the historical low rate of diagnosis and treatment for the conditions being targeted suggests a limited market opportunity, potentially constraining future revenue growth for Avalo's pipeline products.

Avalo Therapeutics (AVTX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Avalo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Avalo Therapeutics (AVTX) Forecast

Analysts have given Avalo Therapeutics (AVTX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Avalo Therapeutics (AVTX) has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Avalo Therapeutics (AVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.